Introduction: The myeloproliferative neoplasms (MPNs) including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases which contribute to significant morbidity. Symptom management is a prime objective in MPN treatment but current symptom assessment tools have not been validated compared to the general population. Materials and Methods: The MPN-Symptom Assessment Form (MPN-SAF) is a reliable and validated clinical tool used to assess MPN symptom burden. The MPN-SAF was administered to MPN patients (n=106) and, for the first time, General Practice and non-blood relative/family controls (n=124) as part of a UK pilot case-control study. Mean symptom scores were compared between cases and controls adjusted for potential confounding variables. Mean patient scores were then compared to data collected by the Mayo Clinic, USA on 1,446 MPN patients to determine the representativeness of the patient group. Results: MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (p
|Publication status||Published - 2016|
|Event||Haematology Association of Ireland Conference - Athlone, Ireland|
Duration: 14 Oct 2016 → 15 Oct 2016
|Conference||Haematology Association of Ireland Conference|
|Period||14/10/16 → 15/10/16|
Anderson, L., James, G., Duncombe, A. S., Mesa, R., Scherber, R., Dueck, A., De Vocht, F., Clarke, M., & McMullin, M. (2016). MYELOPROLIFERATIVE NEOPLASM SYMPTOM BURDEN AND QUALITY OF LIFE: RESULTS FROM THE PILOT MOSAICC STUDY. Paper presented at Haematology Association of Ireland Conference, Athlone, Ireland.